Karthik Kuppusamy

SVP Karthik Kuppusamy sold 8,147 shares of DGX at $200.00 on 2026-06-04 via 10b5-1 plan; retains 13,510 shares post-transaction.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, executed a scheduled sale of 8,147 shares at $200.00 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 21,657 to 13,510 shares. The sale represents a reduction of approximately 37.6% of his pre-transaction holdings, valued at $1,629,400.00. This transaction is mechanical and calendar-driven rather than discretionary; his prior three trades at DGX (two sales on 2025-07-30 and one on 2025-07-31) generated 30-day returns of +8.5%, +8.5%, and +6.8% respectively, with 90-day returns of +6.5%, +6.5%, and +2.8%, indicating his past DGX sales preceded subsequent stock appreciation. At the current price of $197.21, the stock is -7.6% from its 52-week high of $213.50, and DGX trades at a P/E of 21.32 on recent revenue growth of +11.8% year-over-year, suggesting fundamentals remain intact despite the recent pullback.

SVP Karthik sold 10,479 shares (~55% of holdings) for $1,759,930.60 across 3 transactions

KUPPUSAMY KARTHIK, SVP of Clinical Solutions, executed 3 separate sales totaling 10,479 shares for $1,759,930.60, reducing his stake by 55.4% (from 18,929 to 8,450 shares). The sales occurred at prices between $167.40 and $170.00 on 2025-07-30 and 2025-07-31, close to the 52-week high of $182.07. The blended average transaction price of $167.95 exceeds the current price of $170.85, though the stock has declined 3.3% over 30 days and 4.0% over 90 days, suggesting these were recently executed at favorable price points. The magnitude of the reduction (>55% of pre-transaction holdings) is material for an executive of his level, though continued retention of 8,450 shares indicates some remaining equity interest.